Biosimilars Dermatology Roundup for March 2024—Podcast Edition

On this episode of Not So Different, The Center for Biosimilars® discusses all the conference coverage, adalimumab data, and market insights to come out of the biosimilar dermatology space in March 2024.

1. AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
2. Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics
3. Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
4. Adalimumab Expenditures in Countries With and Without Available Biosimilars
5. Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
6. Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
7. Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More